OMIC - Singular Genomics Systems PEG multiplikatori
Farmatsevtika mahsulotlariga talab barqarorligicha qolmoqda, biroq sanksiyalar xomashyo yetkazib berishga salbiy ta'sir ko'rsatmoqda. PEG koeffitsiyenti tendentsiyasi Singular Genomics Systems (OMIC) kompaniyasining joriy baholashini aks ettiradi, bunda parametr 0.00 ni tashkil etadi. O'sish sekvenslash tizimlarini joriy etish bo'yicha laboratoriyalar bilan hamkorlik orqali qo'llab-quvvatlanmoqda, garchi kapital talab qiluvchi R&D va marketing ehtiyojlari kompaniyaning erkin pul oqimini vaqtincha cheklayotgan bo'lsa-da.
Singular Genomics Systems (OMIC) - koʻrsatkichlar kesimi va moliyaviy hisobotlar
- bozor qiymati va tahlilchilarning maqsadli prognozi:
- bozor kapitallashuvi statistikasi:
- balans bo'yicha xususiy kapital ma'lumotlari:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Barcha qarzlarning o‘z mablag‘lariga nisbati Singular Genomics Systems|OMIC - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati singulargenomics.com|OMIC - Kompaniyaning jamlangan qarzlari|Qarzning sof aktivlarga nisbati Singular Genomics Systems Inc|OMIC - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Singular Genomics|Shoshilinch likvidlik koeffitsiyenti singulargenomics.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
OMIC - Kompaniyaning sof foydasi|Kutilayotgan sof foyda Singular Genomics Systems|OMIC - Narxning foydaga nisbati|Prognoz qilingan narxning foydaga nisbati Singular Genomics Corp|OMIC - PEG multiplikatori|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Singular Genomics Systems Inc|OMIC - EBITDA operatsion foydasi|So'nggi 12 oy davomida bir aksiya uchun sof foyda Singular Genomics|OMIC - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi singulargenomics.com|OMIC - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi Singular Genomics Systems
Kompaniyaning umumiy tahlili:Singular Genomics Systems
Investorlar Singular Genomics (OMIC) kompaniyasining barqarorligini P/E koeffitsientini foyda o'sish sur'atlari bilan solishtirish orqali bahlamoqdalar, bu esa qiymat birdan pastga tushganda aktivlarning qadrini past baholashni aniqlash imkonini beradi. Og'irlangan PEG koeffitsientining tahlili strategik moslashuv jarayonida rahbariyat sekvenslash platformasi qiymatini himoya qila olish-olmasligini, shuningdek, operatsion risklarni fundamental kapitalizatsiya salohiyatiga aylantira olishini aniqlashga yordam beradi.
Raqobatdosh kompaniyalar
Tempus AI, Inc (TEM) - Narxning sof foyda o‘sishiga nisbati|Qiagen Group - Narx-foyda va o‘sish multiplikatori|PEG multiplikatori Isis Pharmaceuticals IONS|RGEN - Narxning foydaga va o‘sish sur’atiga nisbati|RNA: Narxning foydaga va o‘sish sur’atiga nisbati|CRSP: PEG multiplikatori|GeneDx Holdings (WGS) - PEG multiplikatori|Narxning foydaga va o‘sish sur’atiga nisbati Ultragenyx Pharma|BEAM: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|Narx-foyda va o‘sish multiplikatori SRPT (Sarepta Therapeutics, Inc.)|TWST (twistbioscience.com) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori TXG (10x Genomics)|Narxning sof foyda o‘sishiga nisbati Intellia Therapeutics Inc|Stoke - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda BioLife|Wave Life Sciences (WVE) - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sishni hisobga olgan narx-foyda koeffitsiyenti MAZE|Narxning foydaga va o‘sish sur’atiga nisbati Sionna Therapeutics|O‘sish sur’atiga tuzatilgan narx-foyda Prime Medicine Inc PRME|Narxning foydaga va o‘sish sur’atiga nisbati Taysha (TSHA)|Narx-foyda va o‘sish multiplikatori uniQure Pharma QURE|PEG multiplikatori MGTX (MeiraGTx Holdings plc)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati regenxbio.com (RGNX)|Solid Biosciences - PEG multiplikatori|Ocugen Inc (OCGN) - Narx-foyda va o‘sish multiplikatori|Pacific Biosciences of California (PACB) - Narxning foydaga va o‘sish sur’atiga nisbati|BNTC - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narx-foyda va o‘sish multiplikatori DSGN|RCKT: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|Narxning foydaga va o‘sish sur’atiga nisbati 4D Molecular Therapeutics, Inc. (FDMT)|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati lexeotx.com|Korro Bio - Narx-foyda va o‘sish multiplikatori|Editas Corp (EDIT) - O‘sish sur’atiga tuzatilgan narx-foyda|SLN - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati ProQR Therapeutics N.V. PRQR|CDXS (codexis.com) - Narx-foyda va o‘sish multiplikatori|SGMO: Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|NAUT (Nautilus Biotechnology, Inc.) - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda Metagenomi Therapeutics MGX|Narxning foydaga va o‘sish sur’atiga nisbati Precision BioSciences (DTIL)|Narx-foyda va o‘sish multiplikatori generationbio.com GBIO|Narxning foydaga va o‘sish sur’atiga nisbati Boundless Bio BOLD|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Exicure Inc. (XCUR)|IMNN - Narxning foydaga va o‘sish sur’atiga nisbati|O‘sish sur’atiga tuzatilgan narx-foyda Phio Pharmaceuticals|mustangbio.com (MBIO) - Narxning foydaga va o‘sish sur’atiga nisbati|Narx-foyda va o‘sish multiplikatori TransCode Therapeutics, Inc.|BNGO (Bionano Genomics Inc.) - PEG multiplikatori|Applied DNA Sciences Inc (APDN) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|PEG multiplikatori BLUE|Narx-foyda va o‘sish multiplikatori immunoprecise.com IPA|PEG multiplikatori OMGA (Omega Therapeutics)|RGLS: O‘sishni hisobga olgan narx-foyda koeffitsiyenti|SYRS - Narxning foydaga va o‘sish sur’atiga nisbati|TBIO (Telesis Bio Inc.) - O‘sishni hisobga olgan narx-foyda koeffitsiyenti|TCON: PEG multiplikatori|Unity Biotechnology, Inc (UBX) - PEG multiplikatori
